Literature DB >> 2828480

Growth and phenotypic characteristics of human nevus cells in culture.

M L Mancianti1, M Herlyn, D Weil, J Jambrosic, U Rodeck, D Becker, L Diamond, W H Clark, H Koprowski.   

Abstract

Nevus cells were isolated from the three cutaneous components, epidermis, basal layer, and dermis, of nonmalignant pigmented lesions and were cultured separately in the presence or absence of the phorbol ester 12-0-tetradecanoyl phorbol-13-acetate in medium that supports the rapid proliferation of melanocytic cells. The separation procedure used provided cultures that were essentially free from normal melanocytes (dermis) or fibroblasts (epidermis). In short term culture, nevus cells of all skin compartments expressed markers associated with differentiated melanocytes, such as presence of premelanosomes and melanosomes and elevated tyrosinase levels. Nevus cells also expressed melanoma-associated antigens, such as NGF-receptor, transferrin-related p97, proteoglycan, and HLA-DR as detected with monoclonal antibodies. After several subpassages, cells showed a decreased expression of melanoma-associated antigens, decreased tyrrosinase levels, and melanosomes could no longer be detected. Morphologically, these cells were similar to fibroblasts. The disappearance of melanoma-associated cell surface antigens was concomitant with the appearance of a melanocyte-associated 145 kd protein that might serve as a marker of fibroblast-like differentiation in nevus cells and normal melanocytes. Nevus cell cultures grown in the presence of 12-0-tetradecanoyl phorbol-13-acetate maintained a stable differentiated phenotype throughout their lifespan. As reported earlier, nevus cells in culture, irrespective of the presence or absence of 12-0-tetradecanoyl phorbol-13-acetate, have a finite lifespan in vitro, grow anchorage-independent in soft agar, but do not form tumors when xenografted to nude mice. These studies demonstrate that nevus cells isolated from the epidermal, basal layer, and dermal components of lesional skin can serve as models to characterize the initial steps of tumor progression in a human cell system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828480     DOI: 10.1111/1523-1747.ep12462099

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

Review 1.  Human melanoma: development and progression.

Authors:  M Herlyn
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

Review 2.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 3.  HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition.

Authors:  Michael Campoli; Soldano Ferrone
Journal:  Semin Immunopathol       Date:  2011-04-28       Impact factor: 9.623

4.  BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.

Authors:  Heike Niessner; Tobias Sinnberg; Corinna Kosnopfel; Keiran S M Smalley; Daniela Beck; Christian Praetorius; Marion Mai; Stefan Beissert; Dagmar Kulms; Martin Schaller; Claus Garbe; Keith T Flaherty; Dana Westphal; Ines Wanke; Friedegund Meier
Journal:  Clin Cancer Res       Date:  2017-07-19       Impact factor: 12.531

5.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

Review 6.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

Review 7.  Growth factor independence and growth regulatory pathways in human melanoma development.

Authors:  U Rodeck
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

8.  Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype.

Authors:  M L Mancianti; W H Clark; F A Hayes; M Herlyn
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

9.  Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.

Authors:  Daniela Beck; Heike Niessner; Keiran S M Smalley; Keith Flaherty; Kim H T Paraiso; Christian Busch; Tobias Sinnberg; Sophie Vasseur; Juan Lucio Iovanna; Stefan Drießen; Björn Stork; Sebastian Wesselborg; Martin Schaller; Tilo Biedermann; Jürgen Bauer; Konstantinos Lasithiotakis; Benjamin Weide; Jürgen Eberle; Birgit Schittek; Dirk Schadendorf; Claus Garbe; Dagmar Kulms; Friedegund Meier
Journal:  Sci Signal       Date:  2013-01-29       Impact factor: 8.192

10.  Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression.

Authors:  Julia K Soo; Alastair D Mackenzie Ross; David M Kallenberg; Carla Milagre; W Heung Chong; Jade Chow; Lucy Hill; Stacey Hoare; Rebecca S Collinson; Mehnaz Hossain; W Nicol Keith; Richard Marais; Dorothy C Bennett
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-20       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.